About Biosynth
Biosynth is a Healthcare company based in Thal (Switzerland) founded in 1966, and was acquired by KKR in November 2021. Biosynth is engaged in supplying critical raw materials and services for life sciences and diagnostics. It operates on a Managed Services and Direct-to-Consumer (D2C) model. Biosynth has completed 7 acquisitions, including Cambridge Research Biochemicals, Celares and EUCODIS. Its chief executive, as recorded, is Matt Gunnison. Its website biosynth.com draws about 212 thousand monthly visits. Biosynth offers products and services including Complex Chemicals, Peptides, and Key Biologics. Its focus areas include Biotechnology, Life Sciences, Pharmaceuticals and Drug Manufacturing. Its legal entity is Biosynth Ltd.
Company details
Biosynth is involved in the manufacture and supply of high-quality products for the pharmaceutical, life science, and diagnostic sectors. Operations span across complex chemicals, peptides, and key biologics, addressing needs in food, agrochemistry, and cosmetics industries. Facilities are maintained on three continents with a rapid global distribution network. Custom synthesis and manufacturing services are provided, including GMP manufacturing for clinical and research applications. Expertise in carbohydrates, nucleosides, and enzyme substrates is leveraged to support customer projects. Solutions are tailored to remove barriers in critical projects through problem-solving approaches.
- Headquarters Thal, Switzerland
- Stage Acquired
- SectorsHealthcare
- Phone•••• ••••
- Website biosynth.com
- Social LinkedIn X YouTube
- Acquired by KKR (Nov 2021)
- Legal Name Biosynth Ltd
- Latest Funding Round$545.67K (USD), Grant
Jun 2021
- InvestorsKKR
& 1 more
- Investments & AcquisitionsCambridge Research Biochemicals
& 6 more
- Acquired byKKR
(Nov 2021)
Products & Services of Biosynth
Biosynth offers a comprehensive portfolio of products and services, including Complex Chemicals, Peptides, and Key Biologics.
Complex chemicals are manufactured for research and industry.
Custom peptides are synthesized for various scientific applications.
Biologics are developed for diagnostics and research purposes.
Apps and channels of Biosynth
its YouTube channel Biosynth has 97 subscribers and 30 videos.
Videos from Biosynth
The most watched videos on Biosynth's YouTube channel, Biosynth (97 subscribers). Click a video to play it here.
More on Biosynth.
Funding Insights of Biosynth
- Total Rounds 1
- Last Round Grant — $545,669
- First Round $545,669
(Jun 2021)
- Investors Count 1
All 1 funding rounds of Biosynth with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jun 2021 | $545,669 | Grant | – | – |
2 investors in total: 2 institutional.
Investors in Biosynth
Biosynth has secured backing from 2 investors, including institutional and venture fund investors. Prominent investors backing the company include KKR and European Union.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
Multiple sectors are invested in by this private equity firm. | 1976 | kkr.com | New York, United States | |
Government entites focused on freedom, democracy, equality and the rule of law, promoting peace and stability | 1958 | europa.eu | Brussels, Belgium |
Investor details for Biosynth
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
People of Biosynth
6 people are tracked at Biosynth (3 in leadership, 2 in board & advisors, 1 in team).
| Name | Role | Group |
|---|---|---|
Matt Gunnison | Chief Executive Officer | Leadership |
Kieran Murphy | Chairman | Leadership |
Karl Hubler | CEO | Leadership |
Hansjoerg Streicher | Scientific Advisor | Board & advisors |
Chris Lawson | Scientific Advisor | Board & advisors |
Urs Spitz | Member Board Of Directors | Team |
Complete people profiles for Biosynth
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
Investments & Acquisitions by Biosynth
Biosynth has strategically engaged in corporate development activities, having acquired 7 companies. Notable acquisitions include Cambridge Research Biochemicals, Celares and EUCODIS.
| Company Name | Description | Domain | Location | Founded | Acquired | Amount |
|---|---|---|---|---|---|---|
Complete chemical solutions for industries are developed and manufactured. | viochemicals.com | Zurich, Switzerland | 2001 | Dec 2023 | •••• | |
Synthetic peptides are manufactured with custom synthesis services provided. | pepceuticals.co.uk | Enderby, United Kingdom | 1998 | Sep 2023 | •••• | |
Drug delivery systems using PEGylation for biopharmaceuticals are developed. | celares.com | Berlin, Germany | 2003 | Jul 2023 | •••• | |
Reagents for custom peptide and antibody development are produced. | crbdiscovery.com | 1980 | May 2023 | •••• | ||
Biological reagents are manufactured and marketed for research and diagnostics. | fitzgerald-fii.com | Acton, United States | 1989 | Apr 2023 | •••• | |
Drug research, enzyme identification, biocatalysis, and formulation services are provided. | eucodis-enzymes.com | Vienna, Austria | 2007 | Aug 2022 | •••• | |
Pepscan employs protein mimicry techniques for the R&D of therapeutic drugs and a range of specialty peptide products and services. | pepscan.com | Lelystad, Netherlands | 2000 | Jun 2022 | •••• |
Complete acquisition details for Biosynth
Acquired stakes, deal sources and the complete acquisition history require an active premium plan.
- Acquired stakes
- Deal sources
- Complete history
- Exports
Verified entity values are shown only after access is granted.
Timeline of Biosynth
10 dated milestones of Biosynth across 57 years, from founding to its latest funding, stage changes and deals.
- Founded Biosynth is founded.
- Funding First funding round of $546K.
- Exit Acquired by KKR.
- Acquisition Acquires Pepscan.
- Acquisition Acquires EUCODIS.
- Acquisition Acquires Fitzgerald.
- Acquisition Acquires Cambridge Research Biochemicals.
- Acquisition Acquires Celares.
- Acquisition Acquires Pepceuticals.
- Acquisition Acquires VIO Chemicals.
Web traffic of Biosynth
The website of Biosynth (biosynth.com) receives about 211.7K visits a month.
- Monthly visits211.7K
▲ 17.6% vs previous month
Websites whose visitors overlap most with Biosynth. Affinity shows how closely the audiences match.
| Website | Domain | Audience affinity | Monthly visits | Global rank | Profile |
|---|---|---|---|---|---|
| phoenixpeptide.com | 100% | 102.4K | #300,152 | View details | |
| caymanchem.com | 97% | 393.1K | #148,469 | View details | |
targetmol.com | targetmol.com | 96% | #394,604 | – | |
pepcalc.com | pepcalc.com | 94% | #1,670,487 | – | |
| jenabioscience.com | 94% | 47.7K | #685,479 | View details | |
| •••••••••• | ••••••.com | ••% | •.•M | #••••• | – |
| •••••••••• | ••••••.com | ••% | •.•M | #••••• | – |
| •••••••••• | ••••••.com | ••% | •.•M | #••••• | – |
All 40 similar websites and full traffic analytics for Biosynth
The complete similar-websites list, audience overlap and engagement analytics require an active premium plan.
- 40 similar websites
- Audience overlap
- Engagement analytics
- Traffic by brand
Verified entity values are shown only after access is granted.
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Related news about Biosynth
Complete news archive for Biosynth
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Biosynth
Biosynth was founded in 1966 and raised its 1st funding round 55 years after it was founded.
Biosynth is headquartered in Thal, Switzerland. It is registered at Thal, St. Gallen, Switzerland.
Matt Gunnison is the CEO of Biosynth, as recorded in our data.
Biosynth is involved in the manufacture and supply of high-quality products for the pharmaceutical, life science, and diagnostic sectors. Operations span across complex chemicals, peptides, and key biologics, addressing needs in food, agrochemistry, and cosmetics industries. Facilities are maintained on three continents with a rapid global distribution network. Custom synthesis and manufacturing services are provided, including GMP manufacturing for clinical and research applications. Expertise in carbohydrates, nucleosides, and enzyme substrates is leveraged to support customer projects. Solutions are tailored to remove barriers in critical projects through problem-solving approaches.
Biosynth offers Complex Chemicals, Peptides, and Key Biologics.
Biosynth has made 7 acquisitions, including Cambridge Research Biochemicals, Celares, and EUCODIS.
Biosynth has 2 investors. Key investors include KKR, and European Union.
Biosynth operates through Biosynth Ltd.
Yes. Biosynth was acquired by KKR in November 2021.
The website of Biosynth receives about 212 thousand visits a month.